Tinzaparin sodium

Drug Profile

Tinzaparin sodium

Alternative Names: Innohep; Logiparin

Latest Information Update: 06 Dec 2016

Price : $50

At a glance

  • Originator LEO Pharma; Novo Nordisk
  • Developer LEO Pharma
  • Class Antithrombotics; Glycosaminoglycans; Low molecular weight heparins
  • Mechanism of Action Factor Xa inhibitors; Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Thrombosis

Most Recent Events

  • 07 Oct 2016 Additional efficacy data from the phase III CATCH trial in Thrombosis presented at the 41st European Society for Medical oncology Congress (ESMO-2016)
  • 01 May 2014 LEO Pharma completes a long-term phase III global trial in Thrombosis (Prevention of recurrence of venous thromboembolism in cancer patients) (NCT01130025)
  • 05 Jul 2013 The French Regulatory Authorities (ANSM) approves tinzaparin sodium for long-term treatment of cancer-associated Thrombosis in France
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top